Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor as the most studied biomarker and the best predictor for response for endometrial cancer reported to date
Endometrial carcinomas (ECs) are the most common gynecologic cancers in the western world. The impac...
Background: This study assesses the expressions of estrogen and progesterone receptors in endometri...
Purpose: The expression and involvement of estrogen (ER) and progesterone receptor (PR) is extensive...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Approximately 70-80% of endometrial carcinomas, type I carcinomas, are associated with endometrial h...
INTRODUCTION: The expression of androgen receptor (AR) is not commonly tested or studied in uterine ...
BACKGROUND: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer...
background: Endometrial cancer (EC) is a hormone-driven disease, and androgen receptor (AR) expressi...
There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone recept...
To compare the efficiency of three different estrogen receptor (ER) immunostaining scoring systems b...
BACKGROUND: Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC)....
Cytosolic estrogen and progesterone receptors(ER and PR) are present in female genital organs includ...
OBJECTIVE: The estrogen receptor (ER)-alpha and -beta and progesterone receptor (PR)-A and -B were d...
This paper aims to validate whether hormone receptor expression is associated with longer survival a...
Purpose The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively pl...
Endometrial carcinomas (ECs) are the most common gynecologic cancers in the western world. The impac...
Background: This study assesses the expressions of estrogen and progesterone receptors in endometri...
Purpose: The expression and involvement of estrogen (ER) and progesterone receptor (PR) is extensive...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Approximately 70-80% of endometrial carcinomas, type I carcinomas, are associated with endometrial h...
INTRODUCTION: The expression of androgen receptor (AR) is not commonly tested or studied in uterine ...
BACKGROUND: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer...
background: Endometrial cancer (EC) is a hormone-driven disease, and androgen receptor (AR) expressi...
There is no consensus on the cutoff for positivity of estrogen receptor (ER) and progesterone recept...
To compare the efficiency of three different estrogen receptor (ER) immunostaining scoring systems b...
BACKGROUND: Oestrogen receptor (ER) expression is a prognostic biomarker in endometrial cancer (EC)....
Cytosolic estrogen and progesterone receptors(ER and PR) are present in female genital organs includ...
OBJECTIVE: The estrogen receptor (ER)-alpha and -beta and progesterone receptor (PR)-A and -B were d...
This paper aims to validate whether hormone receptor expression is associated with longer survival a...
Purpose The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial included a prospectively pl...
Endometrial carcinomas (ECs) are the most common gynecologic cancers in the western world. The impac...
Background: This study assesses the expressions of estrogen and progesterone receptors in endometri...
Purpose: The expression and involvement of estrogen (ER) and progesterone receptor (PR) is extensive...